These two offerings combined will bring in about $1.1B of cash, if priced at close to the current market value. The cash portion (~70%) of the Bayer deal is $5.3B (#msg-150629685).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.